120 related articles for article (PubMed ID: 8912578)
1. Fenofibrate-induced photosensitivity.
Leenutaphong V; Manuskiatti W
J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):775-7. PubMed ID: 8912578
[No Abstract] [Full Text] [Related]
2. Photosensitivity induced by fenofibrate.
Leroy D; Dompmartin A; Lorier E; Leport Y; Audebert C
Photodermatol Photoimmunol Photomed; 1990 Jun; 7(3):136-7. PubMed ID: 2081120
[No Abstract] [Full Text] [Related]
3. Fenofibrate-induced myopathy.
Ghosh B; Sengupta S; Bhattacharjee B; Majumder A; Sarkar SB
Neurol India; 2004 Jun; 52(2):268-9. PubMed ID: 15269493
[TBL] [Abstract][Full Text] [Related]
4. [Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].
Cherif O; Karma F; Ben Amor G; Kochbati S; Ben Amor B; Rokbani L
Tunis Med; 1997 Feb; 75(2):87-91. PubMed ID: 9506029
[No Abstract] [Full Text] [Related]
5. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.
Venero CV; Thompson PD; Fernandez AB
Am J Med; 2008 Oct; 121(10):e3-4. PubMed ID: 18823843
[No Abstract] [Full Text] [Related]
6. [Muscular toxicity due to fenofibrate. Apropos of a case].
Giraud P; Cassou M; Paul R; Guidet M
Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):162. PubMed ID: 7063798
[No Abstract] [Full Text] [Related]
7. Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.
Tahmaz M; Kumbasar B; Ergen K; Ure U; Karatemiz G; Kazancioglu R
Ren Fail; 2007; 29(7):927-30. PubMed ID: 17994463
[TBL] [Abstract][Full Text] [Related]
8. Gynecomastia associated with fenofibrate.
Gardette V; Vezzosi D; Maiza JC; Montastruc JL; Olivier P
Ann Pharmacother; 2007 Mar; 41(3):508-10. PubMed ID: 17341535
[TBL] [Abstract][Full Text] [Related]
9. [Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate].
Duda-Król W; Jórasz I; Dabrowska M; Polubiec A; Kusz-Rynkun A
Wiad Lek; 2000; 53(7-8):454-7. PubMed ID: 11070769
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate can increase serum creatinine levels in renal insufficiency.
Paul S; Mohan V
J Assoc Physicians India; 2006 Apr; 54():337. PubMed ID: 16944623
[No Abstract] [Full Text] [Related]
11. Rare side-effects of fenofibrate.
Rabasa-Lhoret R; Rasamisoa M; Avignon A; Monnier L
Diabetes Metab; 2001 Feb; 27(1):66-8. PubMed ID: 11240449
[TBL] [Abstract][Full Text] [Related]
12. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
13. [Fenofibrate photoallergy].
Jeanmougin M; Manciet JR; De Prost Y; Reygagne P; Pinquier L; Dubertret L
Ann Dermatol Venereol; 1993; 120(8):549-54. PubMed ID: 8304714
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.
Angeles C; Lane BP; Miller F; Nord EP
Am J Kidney Dis; 2004 Sep; 44(3):543-50. PubMed ID: 15332227
[TBL] [Abstract][Full Text] [Related]
15. [Fenofibrate, efficacy and tolerance in long-term treatment (author's transl)].
Fromantin M; Gautier D; Quatre JM; Bon R
Therapie; 1981; 36(4):473-6. PubMed ID: 7292431
[No Abstract] [Full Text] [Related]
16. Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.
Magee G; Sharpe PC
J Clin Pathol; 2009 Mar; 62(3):250-3. PubMed ID: 19251953
[TBL] [Abstract][Full Text] [Related]
17. Fenofibrate for hypertriglyceridemia.
Med Lett Drugs Ther; 1998 Jul; 40(1030):68-9. PubMed ID: 9664930
[No Abstract] [Full Text] [Related]
18. Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).
Bailey CJ
Diabet Med; 2006 Feb; 23(2):109-12. PubMed ID: 16433706
[No Abstract] [Full Text] [Related]
19. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
Bergman AJ; Murphy G; Burke J; Zhao JJ; Valesky R; Liu L; Lasseter KC; He W; Prueksaritanont T; Qiu Y; Hartford A; Vega JM; Paolini JF
J Clin Pharmacol; 2004 Sep; 44(9):1054-62. PubMed ID: 15317833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
